NUVA — NuVasive Share News
0.000.00%
Last trade - 00:00HealthcareBalancedMid Cap
- $2.08bn
- $2.80bn
- $1.20bn
Most medical device cos likely to achieve Q3 results targets- JPM
Brief: NuVasive Says Ryan Donahoe Appointed Chief Technology Officer
BTIG sees bright outlook for Globus Medical, J&J in spinal implant market
Brief: Nuvasive Inc - Board Approved An Increase In Size Of Board From Nine To Ten Members
Brief: NuVasive Inc Receives Latest FDA 510(K) Clearance For Pulse Platform And Announces Commercial Launch
Brief: Nuvasive Receives Latest FDA 510(K) Clearance For Pulse Platform And Announces Commercial Launch
NuVasive Inc reports results for the quarter ended in June - Earnings Summary
Brief: Nuvasive Announces Second Quarter 2021 Financial Results
NuVasive Inc expected to post earnings of 44 cents a share - Earnings Preview
Brief: FDA Says Is Informing Health Care Providers About Potential Biocompatibility Concerns Associated With NuVasive Specialized Orthopedics’ Precice Devices
Brief: Nuvasive Receives Latest CE Mark Approval For Pulse Platform And Starts Global Clinical Evaluations
Brief: NuVasive Appoints Daniel J. Wolterman As Independent Board Chair
NuVasive Inc reports results for the quarter ended in March - Earnings Summary
Brief: Nuvasive Announces First Quarter 2021 Financial Results
NuVasive Inc expected to post earnings of 35 cents a share - Earnings Preview
Medtech sector to benefit from improved utilization volumes in Q1 - Credit Suisse
Biden's planned tax hike to have modest impact on healthcare cos - Needham
Brief: Nuvasive's Simplify Disc Receives FDA Approval For Two-Level Cervical Total Disc Replacement
U.S. RESEARCH ROUNDUP- CytomX Therapeutics, Northern Trust, State Street